Robert T. Matheson, M.D.

経歴
医療機関
オレゴンメディカルリサーチセンター １９９８年～現在
9495 SW Locust Street, suite G
Portland OR 97223 USA
503-245-1525
皮膚科学の臨床研究に専念するクリニックの主任研究員
400人以上の研究のための主任または副査
重症アトピー性皮膚炎の皮膚科専門医
ダーマトロジーアソシエイト

１９７９年～１９９８年

9495 SW Locust Street, suite A
Portland OR 97223
医療、外科、および美容皮膚科
1981 年から臨床試験の主任研究員
臨床教授・皮膚科
オレゴン健康科学大学病院（OHSU）
メディカルライセンス
オレゴン＃９７９５
アメリカボード・皮膚科認定医１９７８年

学歴：
サルズバーグ＆モザルテウム大学卒

１９６５年

ユタ州立大学卒 数学科 B.S. １９６９年
ユタ州立大学卒 医学部 M.D. １９７３年
ユタ州立大学 インターン

医科学科 １９７３年～１９７４年

オレゴン健康科学大学病院（OHSU）

皮膚科 １９７６年～１９７９年
皮膚科美容整形外科 １９７９年

アメリカ軍 公衆衛生部門

フェニックスインディアンメディカル学会：
オレゴン皮膚科ソサイエティ
パシフィックノースウエスト皮膚科ソサイエティ
米国皮膚科アカデミー
オレゴン医学アソシエーション
皮膚科研究ソサイエティ
アメリカ連邦臨床研究
皮膚外科アメリカンソサイエティ
臨床研究プロフェッショナルアソシエーション

臨床研究：

Advanced Tissue Sciences
AllerganAmgen
AnacorAstellas
Atrix
Barrier Therapeutics
Bayer
BerlexBoehringer Ingelheim
Bristol-Myers-Squibb

１９７４年

Celgene
Cellgate
CelticCentocor
CombinatoRx
Connetics
CorixaDermikDow
DUSA
Eli Lilly
FerndaleFujisawa
Galderma
Genentech
Genetics Institute
GlaxoSmithKline
Graceway
Halcygen
HanAll Biopharma
HealthPoint
Human Genome Sciences
IDEC
ImmunexIntendis
ISIS
IsolagenJohnson & Johnson
Leo
Matrix
MedicisMediGene
MedImmune
Merck
NanoBio
Novartis
Novum
NycomedOrtho McNeil
Paddock
Parke DavisPeplin
PerrigoPfizerPromius
Regeneron
Research Testing Laboratories
Rhone-Poulenc
Roche
Rorer
Schering Plough
SeronoShionogi
SirtrisStiefelSynta
TalimaTaro
TevaTolerxTolmarVertexViceptWyeth
XOMA
出版・参考文献：

Leonardi, C, Matheson, R, et.al. “Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in
Chronic Plaque Psoriasis.” New England Journal of Medicine, Vol 366, March 2012
Papp, K, …Matheson, RT, et.al. “The Efficacy of Apremilast, a Phosphodiesterase-4
inhibitor in the Treatment of Moderate to Severe Psoriasis: Results of a Phase 2
Randomized Study.” Accepted to The Lancet, April, 2012
Langley, R, …Matheson, R, et.at. “Safety Profile of Intravenous and Subcutaneous
Siplizumab, an Anti-CD2 Monoclonal Antibody, for the Treatment of Plaque Psoriasis:
Results of Two Randomized, double-blind, Placebo Controlled Studies.” International
Journal of Dermatology, Vol 49, July 2010
Szeimies, RM., RT Matheson, et.al. “Topical Methyl Aminolevulinate Photodynamic
Therapy Using Red Light-Emitting Diode Light for Multiple Actinic Keratoses: A

Randomized Study.” Dermatologic Surgery, Vol. 35, Issue 4 pp. 586-592, March 20,
2009.
Bissonnette R….Matheson, R., et.al. “Humanized Anti-CD2 Monoclonal Antibody
Treatment of Plaque Psoriasis: Efficacy and Pharmacodynamic Results of Two
Randomized, Double-Blind, Placebo-Controlled Studies of Intravenous and
Subcutaneous Siplizumab.” Archives of Dermatological Research, July 2009.
Matheson, R, et.al. “Hydrocortisone Butyrate 0.1% Lotion in the Treatment of Atopic
Dermatitis in Pediatric Subjects.” Journal of Drugs in Dermatology, Vol 7, March, 2008
Abramovits, W, …RT Matheson, et.al. “An Evaluation of the Safety and Efficacy of a
Non-Steroidal Cream in the Management of Mild to Moderate Atopic Dermatitis in
Pediatric Subjects.”
Submitted, 2008.
Checketts, S., …RT Matheson, et.al. “A Double-Blind, Randomized, Vehicle-Controlled
Trial to Determine the Efficacy and Safety of Hydrocortisone Butyrate Lotion 0.1% in theTreatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects Aged 3 Months
to Less than 18 Years.” Abstract The Journal of Drugs in Dermatology: New Methods
and Techniques, February 2008.
Matheson, RT, et.al. “Humanized Anti-CD2 Monoclonal Antibody Treatment of PlaquePsoriasis: Efficacy and Pharmacodynamic Results of Randomized, Double-Blind,
Placebo-Controlled Studies of Intravenous and Subcutaneous Siplizumab.” International
Journal of Dermatology, August 2007.
Gordon, KB, RR Blum, KA Papp, RT Matheson, et.al. “Efficacy and Safety of Adalimumab
Treatment in Patients with Moderate to Severe Psoriasis: A Double-Blind, Randomized
Clinical Trial.” Psoriasis Forum, Vol. 13, No. 1, Summer 2007.

Jorizzo, J, RT Matheson, et.al. “Vehicle-Controlled, Double-Blind, Randomized Study of
Imiquimod 5% Cream Allied 3 Days per Week in One or Two courses of Treatment for
Actinic Keratoses on the Head.” Journal of the American Academy of Dermatology, Vol.
57, Issue 2, August 2007.
Menter, A, T Hamilton, R Matheson, et.al. “Improvements in Patient Global Assessmentof Disease Severity, Plaque Psoriasis and Psoriatic Arthristis Pain, and Pruritus with
Adalimumab Therapy.” International Journal of Dermatology, February 2007.
Korman, N…Matheson, R, et.al. “Dosing With 5% Imiquimod Cream 3 Times per Week
for the Treatment of Actinic Keratosis. Results of Two Phase 3, Randomized, Double-

Blind, Parallel-Group Vehicle-Controlled Trials.” Archives of Dermatology, Vol 141, April,
2005
Matheson, RT, B Miller, et.al. “The Evaluation of Maintenance Therapy of Differin® Gel,
0.1 % Vs Vehicle in Subjects with Acne Vulgaris.” Archives of Dermatology, Manuscript,
2005.
Gottlieb AB, RT Matheson, et.al. “A Randomized Trial of Etanercept as Monotherapy
for Psoriasis.” Arch Dermatology, Vol. 139, December 2003.
Leonardi CL, JL Powers, RT Matheson, et.al. “Multicenter Dose-Ranging Study of the
Safety and Efficacy of Etanercept in Patients with Psoriasis.” New England Journal of
Medicine, Vol. 349, November 2003.
Gottlieb AB, RT Matheson, et.al. “Etanercept as Monotherapy for Psoriasis.” Lancet,
Research Letter, 2002.
Matheson RT, et.al. “Subcutaneous Injection of MEDI-507, an Anti-T-cell Monoclonal
Antibody, for the Treatment of Psoriasis: Phase I Results.” Journal of Investigative
Dermatology, Abstract. 2001;117:817.
Gottlieb AB, …RT Matheson, et. al. “Efficacy of Etanercept in Patients with Psoriasis.”
Lancet,Research Letter, 2001.
Matheson RT, et. al. “Subcutaneous Injection of MEDI-507, an Anti-T-cell Monoclonal
Antibody, for the Treatment of Psoriasis: Phase I Results.” European Society for
Dermatologic Research, Abstract. April, 2001.
Wolf J, …RT Matheson, et.al. “Safety and Efficacy of Short-Duration Oral Terbinafine, in
the Treatment of Tinea Corporis or Tinea Cruris in Subjects with HIV or Diabetes.” Cutis,
2001.
Wolf J, …RT Matheson, et.al. “Randomized Trial of Oral Terbinafine for 2 or 4 Weeks in
the Treatment of Tinea Pedis in Subjects with Diabetes.” American Journal of Medicine,
April, 2000.
Matheson, RT (based on interview with). “Advancing the Cause of Research: What You
Need to Know About Participating in a Clinical Trial.” National Psoriasis Foundation
Bulletin, pp. 10-11, January, 2000.

科学展:

6th International Psoriasis Gene to Clinic. December, 2011. “Results of a Single
Aascending Dose Study to Assess the Safety and Tolerability of CNTO 1959 Following IV
or SC Administration in Healthy Subjects and in Subjects with Moderate to Severe
Psoriasis.”
European Academy of Dermatology and Venereology. Annual Meeting, October 2011.
“Secukinumab, a Novel Fully Human Antibody to Interleukin-17A, in the Treatment ofModerate-to-Severe Plaque Psoriasis: Efficacy and Safety Interim Results from a Phase II
Intravenous Induction Dose-Ranging Study.” (Research supported by Novartis
Pharmaceuticals.)
American Academy of Dermatology Annual Meeting, February 2011. “Safety andBioavailablility of Two Calcipotriene Formulations in subjects with Mild to Moderate
Plaque-Type Psoriasis.” Poster Presentation (Research supported by Stiefel, a GSK
company.)
The Congress of the Psoriasis International Network Annual Meeting, July 2010.
“Sustained Efficacy of Ustekinumab for the Treatment of Moderate to Severe Psoriasis
in Initial Responders Continuing with Maintenance Therapy Through Year 3.”
Presentation. (Research supported by Centocor Ortho Biotech, Inc.)
American Academy of Dermatology Annual Meeting, March 2010. “Calcipotriene foam
for the Treatment of Plaque-Type Psoriasis: Results of Two Phase III Studies.” (Researchsupported by Stiefel Laboratories.)
European Academy of Dermatology and Venereology. Annual Meeting, 2009. “AIN457
Demonstrated to be an Effective, Fast Acting Drug for the Treatment of Chronic PlaqueType Psoriasis in a Proof of Concept Trial. (Research supported by Novartis
Pharmaceuticals.)
American Academy of Dermatology Annual Meeting, February 2008. “Improvements inPatient Global Assessment of Disease Severity, Plaque Psoriasis and Psoriatic Arthritis
Pain, and Pain and Pruritus with Adalimumab; Subanalysis of the First 16 Weeks of
Reveal.” Poster Presentation. (Research supported by Abbott Laboratories.)
American Academy of Dermatology Annual Meeting, February 2008. Checketts, S., …RT
Matheson, et.al. “A Double-Blind, Randomized, Vehicle-Controlled Trial to Determine
the Efficacy and Safety of Hydrocortisone Butyrate Lotion 0.1% in the Treatment of Mild
to Moderate Atopic Dermatitis in Pediatric Subjects Aged 3 Months to Less than 18
Years.” Poster Presentation. (Research supported by Therapeutics, Inc.)
8th International Congress on SLE , Shanghai May 2007. “Early Safety Results of MEDI545, an Anti-Interferon-α Monoclonal Antibody, in Patients with Systemic Lupus

Erythematosus in the MI-CP126 Trial.” Poster Presentation. (Research supported by
MedImmune, Inc.)

American Academy of Dermatology Annual Meeting, February 2007. “VehicleControlled, Multicenter Study to Evaluate the Safety and Efficacy of Topically Applied
AN0128 1% Cream for the Treatment of Mild to Moderate Atopic Dermatitis.” Poster
Presentation. (Research supported by Anacor Pharmaceuticals, Inc.)
American Academy of Dermatology Summer Meeting August 2006. “An Open Label
Adrenal Suppression Study of Hydrocortisone Butyrate Lotion 0.1% Used 3. Daily in
Pediatric Subjects Aged 3 Months to Less than 18 Years with Moderate to Severe Atopic
Dermatitis.” Poster Presentation. (Research supported by Therapeutics, Inc.)
American Academy of Dermatology Annual Meeting, March 2006. “A Multicenter,
Randomized, Double Blind, Vehicle Controlled Study of the Safety and Efficacy of
Clobetasol Propionate Emulsion Formulation (EF) Foam, 0.05% in Adolescent and Adult
Subjects with Moderate to Severe Atopic Dermatitis.” Poster Presentation. (Researchsupported by Connetics Corp.)
American Academy of Dermatology Annual Meeting, March 2006. “Consistency of
Response of Infliximab 5mg/kg Maintenance Therapy: Data from Express and ExpressII.” Poster Presentation. (Research supported by Centocor, Inc.,)
American Academy of Dermatology Annual Meeting, February 2005. “Efficacy and
Safety of 0.01% and 0.03% Tacrolimus Cream Versus Cream Vehicle in Mild to Moderate
Atopic Dermatitis.” Poster Presentation. (Research supported by Fujisawa, Inc.)
American Academy of Dermatology Annual Meeting, February 2005. “Impact ofPimecrolimus Cream 1% on Quality of Life in Atopic Dermatitis: Results from the 6Month, Naturalistic Nobel Study.” Poster Presentation. (Research supported by Novartis
Pharmaceuticals Corp.)
World Congress of Cancers of the Skin Annual Meeting, May 2005. “Vehicle-controlled,
Double-Blind Study of Imiquimod 5% Cream 3 Days per Week in 1 or 2 Courses ofTreatment for Actinic Keratosis of the Head.” Poster Presentation. (Research supported
by 3M Health Care)
American Academy of Dermatology Annual Meeting, February 2004. “Imiquimod 5%
Cream Dosed 3 Times Weekly for the Treatment of Actinic Keratosis.”
Poster Presentation. (Research supported by Therapeutics, Inc.)

American Academy of Dermatology Annual Meeting, February 2004. “Infliximab
Improves Signs of Plaque Psoriasis in Patients with Psoriatic Arthritis.” Poster
Presentation. (Research supported by Centocor, Inc.)
American Academy of Dermatology Annual Meeting, February 2004. “The Efficacy of
Infliximab in Specific Areas of the Body.” Poster Presentation. (Research supported byCentocor, Inc.)
IID, Annual Meeting, April 2003. “Results of two Phase II multiple-dose trials of an antiCD80 monoclonal antibody (IDEC-114) in Patients with Psoriasis.” Abstract. (Researchsupported by IDEC)
American Academy of Dermatology, Annual Meeting, March, 2003. “Efficacy and Safetyof Efalizumab (anti-CD11a) in Subjects with Moderate to Severe Plaques Psoriasis.”
Abstract. (Research supported by Genentech)Society of Investigative Dermatology, Annual Meeting, 2002. “Efficacy of Enbrel in
Patients with Psoriasis,” Abstract. (Research supported by Immunex)
American Academy of Dermatology, Annual Meeting, February, 2002. “Efficacy ofEtanercept in Patients with Psoriasis.” Poster Presentation. (Research Supported by
Immunex)
American Academy of Dermatology, Annual Meeting, March, 2001. “Therapy with
Desloratadine for Chronic Idiopathic Urticaria Reduces Interference with Sleep and Daily
Activities.” Poster Presentation. (Research supported by Schering Plough ResearchInstitute, Kenilworth, NJ)